Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02502708
Title Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors NewLink Genetics Corporation
Indications

malignant glioma

malignant ependymoma

brain cancer

medulloblastoma

Therapies

Indoximod

Temozolomide

Age Groups: child | adult
Covered Countries USA


No variant requirements are available.